Dyshomeostasis of serum sodium concentration in congestive heart failure

American Journal of the Medical Sciences

Volumn 340, Issue 1, 2010, Pages 42-47

  Haley, Heather ^a   Ploth, David W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; PLACEBO; RENIN; SODIUM; SPIRONOLACTONE; TOLVAPTAN; VASOPRESSIN;

CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; COST OF ILLNESS; DISEASE EXACERBATION; DIURETIC THERAPY; ELECTROLYTE DISTURBANCE; HEART OUTPUT; HEMODIALYSIS; HEMOFILTRATION; HORMONE RELEASE; HUMAN; HYPONATREMIA; MENTAL PERFORMANCE; MORBIDITY; MORTALITY; OSMOREGULATION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEIZURE; SINGLE DRUG DOSE; SODIUM BALANCE; SODIUM BLOOD LEVEL; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; WATER DEPRIVATION; WATER RETENTION;

EID: 77954648690     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e5939e     Document Type: Conference Paper

References (24)

1. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia Treatment Guidelines 2007: expert panel recommendations. Am J Med 2007;120:S1-21.
2. Reddy P, Mooradian A. Diagnosis and management of hyponatraemia in hospitalised patients. Int J Clin Pract 2009;63:1494-1508
3. Androgue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342: 1581-1589
4. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-168
5. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006;17:1820-1832
6. Arieff AI, Ayus JC. Hip fractures associated with symptomatic hyponatremia (abstract). J Am Soc Nephrol 2001;12:133.
7. Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008;101:583-588
8. Costanzo MR, Guglin ME, Saltzberg MT, et al; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Cardiol 2007;49: 675-683
9. Neuberg GW, Miller AB, O'Connor, CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38
10. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399-403.
11. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-267
12. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399-403.
13. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-1697
14. Nielson S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999;10:647-667
15. Peacock WF, Costanzo, MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009;113:12-19
16. Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009;2:56-62.
17. Hasselblad V, Stough WG, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069
18. Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:20457-20461
19. Kazory A, Ejaz AA, Ross EA. The UNLOAD trial: a "nephrologic" standpoint. J Am Coll Cardiol 2007;50:820.
20. Konstam MA, Gheorghiade M, Burnett JC, et al; the EVEREST Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297: 1319-1331
21. Schrier RW, Gross P, Gheorghiade M, et al; the SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112
22. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin 2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290: F273-8.
23. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure. The Relief for Acutely Fluid-Overloaded Patients with Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-2046
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717